Lotus Eye Financials
| LOTUSEYE | 70.57 2.14 3.13% |
Lotus | Select Account or Indicator |
Please note, the imprecision that can be found in Lotus Eye's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lotus Eye Hospital. Check Lotus Eye's Beneish M Score to see the likelihood of Lotus Eye's management manipulating its earnings.
Lotus Eye Stock Summary
Lotus Eye competes with Varun Beverages, Bodhi Tree, VIP Clothing, Indian Card, and Electronics Mart. Lotus Eye is entity of India. It is traded as Stock on NSE exchange.Specialization | Health Care, Health Care Equipment & Services |
| Instrument | India Stock View All |
| Exchange | National Stock Exchange of India |
| ISIN | INE947I01017 |
| Business Address | SF No 77012, |
| Sector | Health Care Providers & Services |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.lotuseye.org |
| Phone | 91 42 2422 9900 |
You should never invest in Lotus Eye without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Lotus Stock, because this is throwing your money away. Analyzing the key information contained in Lotus Eye's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Lotus Eye Key Financial Ratios
Lotus Eye's financial ratios allow both analysts and investors to convert raw data from Lotus Eye's financial statements into concise, actionable information that can be used to evaluate the performance of Lotus Eye over time and compare it to other companies across industries.| Revenue | 482.1 M | ||||
| Gross Profit | 116.89 M | ||||
| EBITDA | 79.42 M | ||||
| Net Income | 29.14 M | ||||
| Cash And Equivalents | 36.03 M |
Lotus Eye Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 592.3M | 616.0M | 631.9M | 666.3M | 766.2M | 647.5M | |
| Other Current Liab | 7.6M | 23.0M | 20.8M | 23.5M | 21.1M | 19.8M | |
| Net Debt | (47.8M) | (25.5M) | (29.3M) | (15.4M) | (13.9M) | (14.6M) | |
| Cash | 51.8M | 37.9M | 36.0M | 26.5M | 30.5M | 24.9M | |
| Inventory | 17.8M | 23.1M | 27.9M | 32.1M | 36.9M | 27.5M | |
| Other Current Assets | 11.9M | 10.9M | 24.2M | 26.2M | 23.6M | 15.6M | |
| Total Liab | 65.3M | 69.9M | 56.1M | 72.2M | 65.0M | 52.7M | |
| Total Current Assets | 136.0M | 128.6M | 147.1M | 140.2M | 161.2M | 108.0M | |
| Accounts Payable | 23.5M | 25.2M | 23.0M | 34.6M | 31.1M | 22.8M | |
| Net Receivables | 7.4M | 6.7M | 11.7M | 12.6M | 11.3M | 9.7M | |
| Short Term Debt | 2.6M | 2.0M | 1.5M | 4.2M | 4.9M | 5.1M | |
| Retained Earnings | 67.1M | 86.6M | 116.9M | 135.7M | 156.0M | 163.8M | |
| Intangible Assets | 1.6M | 1.2M | 1.0M | 744K | 669.6K | 1.2M | |
| Other Liab | 6.8M | 5.8M | 5.8M | 5.7M | 6.5M | 5.7M | |
| Net Tangible Assets | 499.2M | 510.4M | 525.3M | 544.9M | 626.6M | 561.7M | |
| Other Assets | 49.2M | 50.9M | 46.6M | 33.5M | 38.5M | 46.2M | |
| Long Term Debt Total | 4.0M | 1.4M | 6.7M | 1.9M | 2.2M | 3.3M | |
| Cash And Equivalents | 44.7M | 51.8M | 37.9M | 36.0M | 41.4M | 28.2M | |
| Net Invested Capital | 527.0M | 546.1M | 575.8M | 594.1M | 683.2M | 591.9M | |
| Net Working Capital | 77.9M | 71.1M | 95.2M | 77.9M | 89.6M | 60.5M |
Lotus Eye Key Income Statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 563K | 283K | 976K | 2.0M | 1.8M | 1.5M | |
| Total Revenue | 316.7M | 380.9M | 470.4M | 482.1M | 554.4M | 333.4M | |
| Gross Profit | 160.1M | 192.6M | 250.6M | 135.7M | 156.0M | 185.1M | |
| Operating Income | 14.3M | 36.4M | 50.3M | 100.5M | 115.6M | 121.4M | |
| Ebit | 21.3M | 43.1M | 58.6M | 42.1M | 48.5M | 50.9M | |
| Ebitda | 44.6M | 68.1M | 88.4M | 79.4M | 91.3M | 48.8M | |
| Cost Of Revenue | 156.5M | 188.2M | 219.8M | 346.4M | 398.4M | 418.3M | |
| Income Before Tax | 19.9M | 40.9M | 56.5M | 40.1M | 46.2M | 48.5M | |
| Net Income | 15.7M | 29.8M | 40.8M | 29.1M | 33.5M | 35.2M | |
| Income Tax Expense | 4.2M | 11.1M | 15.7M | 11.0M | 12.6M | 13.3M | |
| Tax Provision | 4.2M | 11.1M | 15.7M | 11.0M | 12.6M | 13.3M | |
| Interest Income | 649K | 1.3M | 976K | 5.0M | 5.7M | 6.0M | |
| Net Interest Income | (649K) | (1.3M) | (976K) | (974K) | (876.6K) | (832.8K) |
Lotus Eye Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | 3.3M | (5.3M) | (4.9M) | (4.2M) | (4.8M) | (4.6M) | |
| Change In Cash | 29.0M | (11.0M) | 4.9M | (23.5M) | (21.2M) | (20.1M) | |
| Free Cash Flow | 22.6M | (2.9M) | 12.9M | 403K | 463.5K | 440.3K | |
| Depreciation | 23.3M | 25.0M | 29.8M | 37.3M | 33.6M | 27.3M | |
| Other Non Cash Items | (8.4M) | (14.7M) | (22.1M) | (7.5M) | (6.7M) | (7.1M) | |
| Capital Expenditures | 4.8M | 46.8M | 31.0M | 56.4M | 64.9M | 36.8M | |
| Net Income | 19.1M | 41.0M | 56.5M | 29.1M | 33.5M | 35.2M | |
| End Period Cash Flow | 98.9M | 87.9M | 92.8M | 69.3M | 79.7M | 50.4M | |
| Net Borrowings | (13.5M) | 2.1M | (2.6M) | (4.1M) | (3.7M) | (3.9M) | |
| Change To Netincome | (8.2M) | 1.4M | (5.0M) | (3.5M) | (4.0M) | (4.2M) | |
| Investments | 4.9M | (39.2M) | (21.9M) | (46.3M) | (41.7M) | (39.6M) |
Lotus Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lotus Eye's current stock value. Our valuation model uses many indicators to compare Lotus Eye value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lotus Eye competition to find correlations between indicators driving Lotus Eye's intrinsic value. More Info.Lotus Eye Hospital is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about 0.63 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Lotus Eye Hospital is roughly 1.60 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Lotus Eye by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Lotus Eye's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Lotus Eye Hospital Systematic Risk
Lotus Eye's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Lotus Eye volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Lotus Eye Hospital correlated with the market. If Beta is less than 0 Lotus Eye generally moves in the opposite direction as compared to the market. If Lotus Eye Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Lotus Eye Hospital is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Lotus Eye is generally in the same direction as the market. If Beta > 1 Lotus Eye moves generally in the same direction as, but more than the movement of the benchmark.
Lotus Eye Hospital Common Stock Shares Outstanding Over Time
Lotus Eye Thematic Clasifications
Lotus Eye Hospital is part of several thematic ideas from Health Management to Management. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasLotus Eye March 25, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Lotus Eye help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lotus Eye Hospital. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lotus Eye Hospital based on widely used predictive technical indicators. In general, we focus on analyzing Lotus Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lotus Eye's daily price indicators and compare them against related drivers.
| Information Ratio | (0) | |||
| Maximum Drawdown | 11.35 | |||
| Value At Risk | (4.37) | |||
| Potential Upside | 6.13 |
Additional Tools for Lotus Stock Analysis
When running Lotus Eye's price analysis, check to measure Lotus Eye's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lotus Eye is operating at the current time. Most of Lotus Eye's value examination focuses on studying past and present price action to predict the probability of Lotus Eye's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lotus Eye's price. Additionally, you may evaluate how the addition of Lotus Eye to your portfolios can decrease your overall portfolio volatility.